Mobia Medical (NASDAQ:MOBI) Price Target Raised to $17.00

Key Points

• JPMorgan raised Mobia Medical’s price target to $17 from $15 and maintained an “overweight” rating, implying 35.24% upside from the prior close.
• Analyst sentiment remains positive, with five Buy ratings and one Hold rating producing a “Moderate Buy” consensus and an average price target of $20.75.
• Mobia Medical’s quarterly revenue more than doubled year over year to $13.51 million, but its $1.10-per-share loss exceeded expectations of $0.83 and the company remains unprofitable.

Mobia Medical (NASDAQ:MOBI - Get Free Report) had its target price upped by JPMorgan Chase & Co. from $15.00 to $17.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price objective suggests a potential upside of 35.24% from the stock's previous close.

MOBI has been the subject of a number of other research reports. Bank of America began coverage on Mobia Medical in a research note on Tuesday, June 2nd. They issued a "buy" rating and a $16.00 target price for the company. Wolfe Research started coverage on Mobia Medical in a report on Tuesday, June 2nd. They issued an "outperform" rating on the stock. The Goldman Sachs Group assumed coverage on Mobia Medical in a research note on Tuesday, June 2nd. They issued a "buy" rating and a $31.00 price objective for the company. Zacks Research upgraded Mobia Medical to a "hold" rating in a research report on Wednesday, June 3rd. Finally, Wall Street Zen upgraded shares of Mobia Medical from a "sell" rating to a "hold" rating in a report on Sunday, June 14th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $20.75.

Mobia Medical Stock Performance

Shares of NASDAQ MOBI traded down $0.01 during trading hours on Wednesday, hitting $12.57. 29,325 shares of the stock were exchanged, compared to its average volume of 145,131. Mobia Medical has a 12 month low of $10.19 and a 12 month high of $15.29. The firm's fifty day simple moving average is $12.54. The firm has a market capitalization of $417.94 million and a P/E ratio of -0.65.

Mobia Medical (NASDAQ:MOBI - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($1.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.27). The firm had revenue of $13.51 million during the quarter. Mobia Medical's revenue for the quarter was up 102.4% compared to the same quarter last year. Research analysts predict that Mobia Medical will post -2.5 EPS for the current year.

Insider Buying and Selling

In related news, CFO Nelson Bunker Curnes bought 5,000 shares of the company's stock in a transaction that occurred on Tuesday, June 9th. The shares were purchased at an average cost of $12.79 per share, with a total value of $63,950.00. Following the completion of the acquisition, the chief financial officer directly owned 366,997 shares in the company, valued at approximately $4,693,891.63. The trade was a 1.38% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Mobia Medical News Roundup

Here are the key news stories impacting Mobia Medical this week:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating and set a $19.00 price target, implying substantial upside from the recent trading level. The endorsement reflects confidence in Mobia Medical’s growth prospects. Benzinga analyst rating report
• Positive Sentiment: Second-quarter revenue rose 102.4% year over year to $13.51 million, while gross margin reached 83.2%. Management also forecast 2026 revenue of $54 million to $56 million, above the approximately $53.5 million analyst consensus, representing expected growth of roughly 69% to 75%. Mobia Medical second-quarter 2026 financial results
• Positive Sentiment: Mobia Medical highlighted two-year VNS-REHAB follow-up data showing durable improvements in upper-limb motor function, daily living activities and quality of life. The company also completed its IPO, raising approximately $134 million in net proceeds, strengthening its funding position. Clinical data and IPO highlights
• Neutral Sentiment: The IPO proceeds and continued commercialization could support expansion, but investors will likely focus on how quickly the company converts revenue growth into profitability.
• Negative Sentiment: Mobia Medical reported a second-quarter loss of $1.10 per share, wider than the analyst consensus loss of $0.83 per share. The company remains unprofitable, with analysts expecting a full-year loss of approximately $2.50 per share, creating pressure despite strong sales growth. Mobia Medical earnings report

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source